EMR changes
Pick any two versions below to diff them.
- Price
- $162.35 → $167.06(+2.9%)
- Balance sheet
- Cash: $1.8B Debt: $12.2B Net debt: $10.4B added: Interest cover: 9.0× Undrawn credit line: $5.5B Debt due within 12 months: $4.7B At September 30, 2026, Emerson had cash and equivalents of $1,806 million. Short-term borrowings and current maturities of long-term debt were $4,667 million, and long-term debt was $7,508 million, for total debt of $12,175 million. In fiscal 2026, Emerson repaid $588 million of long-term debt, paid dividends of $1,244 million and bought back $1,000 million of stock. In February 2026, it entered into a $2 billion 364-day credit facility that expires on February 9, 2027 and backs its commercial paper. added: It also has a $3.5 billion five-year credit facility from February 2023. Emerson has not borrowed under either facility, and the facilities have no financial covenants. Free cash flow was $3,535 million in fiscal 2026. added: Interest cover, earnings before income taxes plus interest expense divided by interest expense, was 9.0 times in fiscal 2026 (10-K filed November 9, 2026). For fiscal 2027, Emerson expects free cash flow of $3.8 billion to $3.9 billion and plans about $2.5 billion of buybacks and about $1.3 billion of dividends. Common stockholders' equity was $20,740 million. As of Sep 30, 2026.